Christopher E Brightling, Marco Caminati, Jean-Pierre Llanos, Scott Caveney, Ales Kotalik, Janet M Griffiths, Anna Lundahl, Elliot Israel, Ian D Pavord, Michael E Wechsler, Celeste Porsbjerg, Jonathan Corren, Monika Gołąbek, Neil Martin, Sandhia Ponnarambil
BACKGROUND: Long-term tezepelumab treatment in the DESTINATION study (NCT03706079) resulted in reduced asthma exacerbations, reduced biomarker levels and improved lung function and symptom control in patients with severe, uncontrolled asthma. OBJECTIVE: To explore time course of changes in biomarkers and clinical manifestations following treatment cessation after 2 years of tezepelumab treatment. METHODS: DESTINATION was a two-year, phase 3, multicenter, randomized, placebo-controlled, double-blind study of tezepelumab treatment in patients (12-80 years old) with severe asthma...
April 30, 2024: Annals of Allergy, Asthma & Immunology